Cargando…

Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis

INTRODUCTION: The overall outcome of patients with refractory AML (rAML) remains poor. Though allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered as the only curative therapy, it is routinely recommended only for patients after remission with salvage chemotherapy. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhong-yu, Gao, Wen-hui, Zhao, Hui-jin, Yin, Chun-rong, Wang, Zi-wei, Tian, Liang, Wang, Ling, Wang, Li-ning, Jiang, Jie-ling, Devillier, Raynier, Wan, Ming, Wang, Jian-Ming, Huang, Ping-ping, Blaise, Didier, Hu, Jiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393842/ https://www.ncbi.nlm.nih.gov/pubmed/35231903 http://dx.doi.org/10.1159/000511144

Ejemplares similares

Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
por: Wang, Ling, et al.
Publicado: (2018)

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis
por: Gao, Wen-hui, et al.
Publicado: (2023)

Salvaged allogeneic hematopoietic stem cell transplantation for pediatric chemotherapy refractory acute leukemia
por: Wang, Jingbo, et al.
Publicado: (2017)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

Metabolomics analysis of salvage chemotherapy on refractory acute myeloid leukemia patients
por: Zheng, Zhi, et al.
Publicado: (2018)

Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated Fusarium solani infection
por: Sheela, Sheenu, et al.
Publicado: (2017)

Busulfan and Fludarabine Conditioning Regimen Given at Hematological Nadir of Cytoreduction Fludarabine, Cytarabine, and Idarubicin Chemotherapy in Patients With Refractory Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation: A Single Arm Pilot Consort Study
por: Tang, Wei, et al.
Publicado: (2015)

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
por: Mühleck, Regina, et al.
Publicado: (2021)

Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia
por: Martino, R, et al.
Publicado: (1998)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study
por: Xu, Jun, et al.
Publicado: (2018)

Efficacy of Adding Bortezomib to Salvage Chemotherapy in Relapsed/refractory Acute Myeloid Leukemia a Prospective Non-Interventional Study
por: Ghadiany, Mojtaba, et al.
Publicado: (2021)

Clinical Significance of Haplo-Fever and Cytokine Profiling After Graft Infusion in Allogeneic Stem Cell Transplantation From Haplo-Identical Donors
por: Wang, Lining, et al.
Publicado: (2022)

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor
por: Devillier, Raynier, et al.
Publicado: (2021)

P1302: SALVAGE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS ALSO THE CURATIVE AND SAFE TREATMENT FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN THE ERA OF TARGETED THERAPY
Publicado: (2023)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)

Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Dou, Li-Ping, et al.
Publicado: (2018)

Myeloid malignancies: mutations, models and management
por: Murati, Anne, et al.
Publicado: (2012)

Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia
por: Li, Kening, et al.
Publicado: (2022)

PB1810: OUTCOME OF ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANT: A SINGLE INSTITUTION RETROSPECTIVE STUDY
por: Castoldi, C., et al.
Publicado: (2022)

Genetic changes in refractory relapsed acute myeloid leukemia with NPM1 mutation: A case report
por: Wang, Shuang-Ling
Publicado: (2022)

Manufacturing Natural Killer Cells as Medicinal Products
por: Chabannon, Christian, et al.
Publicado: (2016)

Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
por: da Silva, Wellington Fernandes, et al.
Publicado: (2020)

A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia
por: Wang, Jingbo, et al.
Publicado: (2018)

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
por: Jiang, Xuejie, et al.
Publicado: (2015)

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial
por: Zhang, Chengtao, et al.
Publicado: (2023)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
por: Kaimila, Bongani, et al.
Publicado: (2017)

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
por: Gelsi-Boyer, Véronique, et al.
Publicado: (2012)

Erratum for: Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience
Publicado: (2020)

Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
por: Ferraro, Francesca, et al.
Publicado: (2022)

MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia
por: Niu, Mingshan, et al.
Publicado: (2019)

MRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Hao, Qi, et al.
Publicado: (2021)

Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia
por: Schmaelter, Ann-Kristin, et al.
Publicado: (2020)

Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid Malignancies: A Single Arm Phase II Study
por: Jiang, Jie-ling, et al.
Publicado: (2021)

Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia
por: Horvat, Nathan P, et al.
Publicado: (2022)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Anders, Brandi, et al.
Publicado: (2017)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

P578: EFFECTIVENESS OF REINDUCTION CHEMOTHERAPY USING BORTEZOMIB WITH HOMOHARRINGTONINE AND CYTARABINE IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA: A PHASE II, MULTICENTER, PROSPECTIVE CLINICAL TRIAL
por: Zhang, Chengtao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5vivimq99n5pepk9s5gib05egu